Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹10Cr
Rev Gr TTM
Revenue Growth TTM
-21.33%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

PHYTO
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 45.4 | -54.6 | -42.2 | -17.4 | -91.0 | 620.3 | -39.4 | -43.9 | 224.4 | -67.5 | -0.2 | -18.6 |
| 4 | 2 | 7 | 6 | 4 | 6 | 4 | 3 | 3 | 2 | 5 | 3 |
Operating Profit Operating ProfitCr |
| 12.8 | -200.0 | 7.5 | 11.7 | -731.1 | -22.3 | 12.8 | 4.7 | -71.9 | -34.0 | -10.1 | -8.4 |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | -2 | 0 | 0 | -2 | -1 | 0 | 2 | -1 | -1 | -1 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Growth YoY PAT Growth YoY% | 140.0 | -12.1 | -108.1 | 193.6 | -1,525.0 | 16.5 | 168.8 | 424.1 | 32.2 | 67.3 | -609.1 | -131.6 |
| 2.4 | -275.0 | -2.2 | 4.5 | -380.0 | -31.9 | 2.5 | 41.6 | -79.5 | -32.0 | -12.8 | -16.2 |
| 0.3 | -4.1 | -0.4 | 0.7 | -4.0 | -3.4 | 0.3 | 3.5 | -2.7 | -1.1 | -1.3 | -1.1 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| 39.3 | -46.6 | 104.0 | 25.9 | 0.0 | -25.2 | 0.6 | -48.0 | 15.8 | -44.6 | -4.9 | -26.9 |
| 40 | 22 | 44 | 57 | 57 | 42 | 42 | 22 | 24 | 18 | 15 | 13 |
Operating Profit Operating ProfitCr |
| 6.2 | 6.6 | 6.1 | 3.6 | 4.1 | 4.3 | 5.0 | 6.1 | 9.7 | -22.1 | -9.6 | -21.9 |
Other Income Other IncomeCr | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 2 |
Interest Expense Interest ExpenseCr | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | -3 | -1 | -3 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| -11.2 | -80.0 | 673.2 | 8.6 | -20.9 | -38.7 | 10.6 | -53.4 | -3.3 | -1,597.6 | 70.2 | -170.3 |
| 1.3 | 0.5 | 1.8 | 1.6 | 1.2 | 1.0 | 1.1 | 1.0 | 0.8 | -22.5 | -7.0 | -26.0 |
| 1.3 | 0.3 | 2.0 | 2.1 | 1.7 | 1.0 | 1.1 | 0.5 | 0.5 | -7.8 | -2.3 | -6.3 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| 3 | 4 | 4 | 5 | 5 | 6 | 6 | 6 | 6 | 3 | 2 | 1 |
Current Liabilities Current LiabilitiesCr | 25 | 19 | 31 | 45 | 60 | 53 | 30 | 24 | 25 | 21 | 20 | 19 |
Non Current Liabilities Non Current LiabilitiesCr | 2 | 3 | 2 | 3 | 4 | 4 | 5 | 4 | 4 | 3 | 2 | 1 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 31 | 25 | 38 | 53 | 67 | 62 | 41 | 34 | 36 | 28 | 25 | 22 |
Non Current Assets Non Current AssetsCr | 4 | 4 | 4 | 5 | 6 | 6 | 4 | 4 | 4 | 4 | 3 | 3 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | -2 | 0 | 2 | 1 | 3 | 1 | -1 | 3 | 1 | 3 | 2 |
Investing Cash Flow Investing Cash FlowCr | 0 | 1 | 0 | 0 | -1 | 0 | 1 | 0 | 0 | 0 | 1 |
Financing Cash Flow Financing Cash FlowCr | 2 | 0 | -2 | -1 | -2 | -1 | 0 | -3 | -2 | -3 | -3 |
|
Free Cash Flow Free Cash FlowCr | -2 | 0 | 1 | -1 | 2 | 1 | 0 | 3 | 1 | 3 | |
| -390.3 | -314.0 | 181.5 | 83.3 | 384.8 | 334.0 | -144.3 | 1,482.0 | 640.5 | -102.5 | -178.5 |
CFO To EBITDA CFO To EBITDA% | -80.4 | -22.7 | 53.5 | 35.5 | 115.3 | 77.6 | -32.3 | 241.8 | 54.7 | -104.5 | -131.7 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 12 | 13 | 23 | 25 | 12 | 8 | 7 | 9 | 14 | 14 | 12 |
Price To Earnings Price To Earnings | 21.4 | 111.7 | 26.7 | 27.7 | 17.2 | 17.3 | 14.9 | 38.2 | 63.1 | 0.0 | 0.0 |
Price To Sales Price To Sales | 0.3 | 0.6 | 0.5 | 0.4 | 0.2 | 0.2 | 0.2 | 0.4 | 0.5 | 0.9 | 0.9 |
Price To Book Price To Book | 1.5 | 1.6 | 2.7 | 2.9 | 1.3 | 0.8 | 0.7 | 0.8 | 1.3 | 1.9 | 1.9 |
| 10.1 | 18.8 | 14.3 | 20.2 | 14.1 | 15.4 | 12.0 | 21.1 | 12.9 | -9.7 | -21.0 |
Profitability Ratios Profitability Ratios |
| 27.8 | 35.8 | 30.1 | 19.4 | 16.1 | 20.4 | 20.6 | 34.2 | 33.0 | 12.2 | 17.7 |
| 6.2 | 6.6 | 6.1 | 3.6 | 4.1 | 4.3 | 5.0 | 6.1 | 9.7 | -22.1 | -9.6 |
| 1.3 | 0.5 | 1.8 | 1.6 | 1.2 | 1.0 | 1.1 | 1.0 | 0.8 | -22.5 | -7.0 |
| 10.5 | 8.0 | 10.6 | 12.3 | 9.6 | 9.1 | 8.8 | 7.2 | 7.9 | -5.0 | 3.6 |
| 7.0 | 1.4 | 10.2 | 10.4 | 7.7 | 4.5 | 4.8 | 2.2 | 2.1 | -45.3 | -15.5 |
| 1.5 | 0.4 | 2.0 | 1.6 | 1.0 | 0.7 | 1.1 | 0.6 | 0.6 | -10.5 | -3.6 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
Phyto Chem (India) Limited is an established Indian agrochemical player currently undergoing a strategic pivot. While its historical core competency lies in the manufacturing of pesticide formulations, the company is aggressively diversifying into industrial sectors—specifically ferroalloys—to mitigate the volatility of the agricultural market and drive a recovery in shareholder value.
---
### **Core Manufacturing Capabilities & Infrastructure**
The company operates a centralized, integrated manufacturing hub in Southern India, focusing on self-reliance and indigenous technical development.
* **Integrated Facility:** The primary manufacturing unit and registered office are located at **Bonthapally, Sangareddy District, Telangana**.
* **Production Capacity:** The facility maintains a total production capacity of **90,00,000 Liters/Kilograms** per annum.
* **Technological Independence:** The company utilizes **100% indigenous technology**. No foreign technology has been imported in the last **three years**, reflecting a self-sustained operational model.
* **R&D and Innovation:** An in-house Research & Development division focuses on developing **new viable products** and optimizing existing manufacturing processes. R&D costs are integrated into operational expenses rather than accounted for separately.
* **Sustainability Initiatives:** Management is currently evaluating the installation of **Solar Street Lights** and **Solar Panels** to power plant lighting and reduce carbon footprints.
---
### **Strategic Business Segments**
Phyto Chem has restructured its operations into three distinct segments to balance seasonal agricultural risks with steady industrial demand.
| Segment | Focus Area | Status |
| :--- | :--- | :--- |
| **Pesticide Formulations** | Liquid/SC, Weedicides, Wettable Powders, and Granules. | Core / Consolidating |
| **Ferro Alloy Products** | Manufacturing and supply under a loan licensing agreement. | High-Growth / New |
| **Real Estate** | Sale of residual land parcels and price escalation settlements. | Secondary / Residual |
* **Pesticides (Agri-Business):** Operates through an established dealer network across **Telangana, Andhra Pradesh, Maharashtra, and Karnataka**. Due to intense competition, the company has intentionally avoided exports, focusing exclusively on the domestic market where it can leverage its brand.
* **Ferroalloys (Industrial-Business):** Launched in **FY 2024-25** via a manufacturing loan licensing agreement with **M/s. Siri Smelters & Energy Private Limited**. This segment has rapidly scaled, contributing **30% to 42%** of total sales in recent quarters and providing a much-needed profit cushion of **₹66.79 lakhs** as of December 2024.
* **Real Estate:** While not a core focus, this segment provides periodic liquidity. The company received price escalation settlements of **₹2 crore** in **FY 2023-24** and **₹1.5 crore** in **FY 2024-25**.
---
### **Financial Performance & Recovery Targets**
The company is emerging from a period of financial contraction characterized by a **36.36%** turnover decrease in **FY 2023-24**. Management has set aggressive targets for a turnaround.
**Revenue and Profitability Trajectory:**
* **FY 2022-23:** Turnover of **₹26.92 crore** with a PAT of **₹0.22 crore**.
* **FY 2023-24:** Turnover dropped to **₹17.13 crore** with a Net Loss of **₹(3.33) crore**.
* **FY 2024-25 (Est):** Turnover of **₹16.55 crore** with a narrowed Net Loss of **₹(0.97) crore**.
* **FY 2025-26 (Target):** Management is targeting a total turnover of **₹32.75 crore**—representing a projected growth of approximately **98%**, driven primarily by the Ferroalloy expansion.
**Capital Structure & Liquidity:**
* **Paid-up Capital:** **₹4.3 crore** (43,00,200 shares at **₹10/-** par value).
* **Market Valuation:** Market Capitalization stood at **₹1,374.77 lakhs** (as of March 31, 2024) with a closing price of **₹31.97** on the BSE.
* **Working Capital:** Secured by the hypothecation of inventory and book debts, further supported by personal guarantees from the **Managing Director** and **Executive Director**. Cash and equivalents remained tight at **₹4.61 lakhs** as of March 2025.
---
### **Operational Risks & Mitigation Strategies**
Phyto Chem operates in a high-risk environment influenced by climate, credit, and competition.
* **Climatic & Market Volatility:** The pesticide business is highly sensitive to **monsoon conditions**. Recent shortfalls in rain led to reduced crop acreage. To mitigate this, the company is shifting weight toward the **Ferroalloy market**, which it views as "highly reliable."
* **Credit Risk:** The industry demands an **unlimited credit period**, leading to challenges in timely collections. The company has implemented the **Ind AS 109 Expected Credit Loss (ECL)** model to better manage receivables.
* **Cost Pressures:** Manufacturing expenses as a percentage of sales rose from **69.15%** to **79.55%** in one year. In response, the company initiated **Cost Rationalization**, including a **24.23%** reduction in Managerial Remuneration and a **10.98%** reduction in general employee salaries.
* **Foreign Exchange:** Outflow for raw materials was reduced from **₹1.24 crore** in **FY 2022-23** to **Nil** in the most recent period, as the company pivoted away from import-heavy requirements.
---
### **Governance & Leadership**
To ensure stability during its strategic transition, the company has secured long-term commitments from its top leadership and is strengthening board oversight.
* **Executive Leadership:**
* **Mr. Y. Nayudamma (Managing Director):** Re-appointed for a 3-year term through **December 2027**.
* **Mr. Y. Janaki Ramaiah (Executive Director):** Re-appointed for a 5-year term effective **July 2024**.
* **Board Composition:** Recent appointments of Independent Directors, including **Mr. M. Sree Ram Murthy** and **Mr. N. Nagendra Naidu**, aim to address previous difficulties in finding suitable candidates from the national data bank.
* **Compliance Note:** The company is working to resolve historical administrative delays, including a **333-day delay** in filing Form MGT-14 for the **FY 2023-24** Directors' Report.
---
### **Investment Outlook**
Phyto Chem (India) Limited is currently a "transition story." The legacy pesticide business provides a foundation of infrastructure and brand presence, but the **Ferroalloy segment** is the intended engine for future margin expansion. Investors should monitor the company’s ability to hit its **₹32.75 crore** revenue target for **FY 2025-26** and its success in managing working capital cycles in a high-competition domestic market.